TP53 and prostate carcinoma: We subsequently performed the same experiment using the AA patient‐derived RC77T prostate cancer cell line, and the results were essentially the same (Fig. 4D–F, Fig. S4), underscoring that although a molecular phenotype may be enriched in PCa from AAM (i.e., TP53 wild‐type, IL‐6 derived from the environment), it is not exclusive to PCa from AAM.